FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209858460> ?p ?o ?g. }

• W3209858460 abstract "Abstract Background The REPLACE study investigated the effect of switching to riociguat (RIO) in patients with pulmonary arterial hypertension receiving PDE5i but still at intermediate risk. The centrally adjudicated composite primary endpoint was clinical improvement in the absence of clinical worsening, where clinical improvement was defined as meeting at least two of the following criteria: 6-minute walk distance (6MWD), increase by ≥10% or ≥30 m from baseline (BL) to Wk 24; World Health Organization functional class (WHO FC) I or II at Wk 24; or N-terminal prohormone of brain natriuretic peptide reduction of ≥30% from BL to Wk 24. Twice as many patients switching to RIO (45/111, 41%) met the primary endpoint compared with those remaining on PDE5i (23/113, 20%); odds ratio (OR): 2.78 (95% confidence interval [CI] 1.53–5.06); p=0.0007. Purpose Assess changes in right and left ventricular (RV; LV) function using cardiac magnetic resonance imaging (cMRI) in a subgroup of patients participating in REPLACE. Methods REPLACE was a randomised, open-label, 24-week, Phase 4 study (NCT02891850). Patients in WHO FC III, with 6MWD 165–440 m, were randomised to switch to RIO 2.5 mg–max tid or remain on PDE5i. Background endothelin receptor antagonist therapy was permitted in both arms. cMRI was performed on a subset of patients from the full analysis set as an exploratory substudy. The following parameters were measured at BL and Wk 24: RV and LV end-diastolic and end-systolic volumes (RVEDV; RVESV; LVEDV; LVESV), RV stroke volume and stroke volume index (RVSV; RVSVI), LV stroke volume (LVSV), RV ejection fraction (RVEF), and pericardial effusion. Results Twenty-seven patients participated in the cMRI substudy. This comprised 11/111 (10%) patients in the RIO arm (mean [standard deviation {SD}] 40.0 [12.4] years), and 16/113 (14%) patients (mean 44.5 [17.6] years) in the PDE5i arm. Like the main population, the treatment response in the cMRI subpopulation favoured RIO versus PDE5i (OR: 6.11 [95% CI 0.90–41.60]). From BL to Wk 24, RVEDV and RVESV decreased in the RIO treatment arm but increased in the PDE5i treatment arm (Table 1). Similar, but less pronounced, changes were observed for the left ventricle (LVESV, LVEDV). RVSV and RVEF levels were close to normal at BL and did not increase in either arm at Wk 24 (Table 1). Pericardial effusion, which was present in 5 patients in each group at BL, decreased in 1 patient in the RIO arm and no patients in the PDE5i arm. Conclusions Decreases in RVEDV and RVESV suggest improvements in cardiac function in the RIO arm compared with the PDE5i arm. Values for RVEF and RVSVI were close to normal at BL and did not change at Wk 24. Improvements in cMRI parameters were in line with the clinical improvement observed in patients switching to RIO in the overall population. FUNDunding Acknowledgement Type of funding sources: Other. Main funding source(s): The REPLACE study was co-funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, NJ, USA)" @default.
• W3209858460 created "2021-11-08" @default.
• W3209858460 creator A5016773092 @default.
• W3209858460 creator A5024507792 @default.
• W3209858460 creator A5025707623 @default.
• W3209858460 creator A5031477165 @default.
• W3209858460 creator A5032856939 @default.
• W3209858460 creator A5040574354 @default.
• W3209858460 creator A5048931724 @default.
• W3209858460 creator A5051516010 @default.
• W3209858460 creator A5057929462 @default.
• W3209858460 creator A5059706401 @default.
• W3209858460 creator A5091783313 @default.
• W3209858460 date "2021-10-01" @default.
• W3209858460 modified "2023-10-16" @default.
• W3209858460 title "Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy" @default.
• W3209858460 doi "https://doi.org/10.1093/eurheartj/ehab724.1966" @default.
• W3209858460 hasPublicationYear "2021" @default.
• W3209858460 type Work @default.
• W3209858460 sameAs 3209858460 @default.
• W3209858460 citedByCount "0" @default.
• W3209858460 crossrefType "journal-article" @default.
• W3209858460 hasAuthorship W3209858460A5016773092 @default.
• W3209858460 hasAuthorship W3209858460A5024507792 @default.
• W3209858460 hasAuthorship W3209858460A5025707623 @default.
• W3209858460 hasAuthorship W3209858460A5031477165 @default.
• W3209858460 hasAuthorship W3209858460A5032856939 @default.
• W3209858460 hasAuthorship W3209858460A5040574354 @default.
• W3209858460 hasAuthorship W3209858460A5048931724 @default.
• W3209858460 hasAuthorship W3209858460A5051516010 @default.
• W3209858460 hasAuthorship W3209858460A5057929462 @default.
• W3209858460 hasAuthorship W3209858460A5059706401 @default.
• W3209858460 hasAuthorship W3209858460A5091783313 @default.
• W3209858460 hasBestOaLocation W32098584601 @default.
• W3209858460 hasConcept C126322002 @default.
• W3209858460 hasConcept C127413603 @default.
• W3209858460 hasConcept C142724271 @default.
• W3209858460 hasConcept C156957248 @default.
• W3209858460 hasConcept C164705383 @default.
• W3209858460 hasConcept C203092338 @default.
• W3209858460 hasConcept C204787440 @default.
• W3209858460 hasConcept C27081682 @default.
• W3209858460 hasConcept C2775846464 @default.
• W3209858460 hasConcept C2775915353 @default.
• W3209858460 hasConcept C2776304953 @default.
• W3209858460 hasConcept C2777428986 @default.
• W3209858460 hasConcept C2778198053 @default.
• W3209858460 hasConcept C2780645631 @default.
• W3209858460 hasConcept C2780930700 @default.
• W3209858460 hasConcept C44249647 @default.
• W3209858460 hasConcept C535046627 @default.
• W3209858460 hasConcept C71924100 @default.
• W3209858460 hasConcept C78519656 @default.
• W3209858460 hasConceptScore W3209858460C126322002 @default.
• W3209858460 hasConceptScore W3209858460C127413603 @default.
• W3209858460 hasConceptScore W3209858460C142724271 @default.
• W3209858460 hasConceptScore W3209858460C156957248 @default.
• W3209858460 hasConceptScore W3209858460C164705383 @default.
• W3209858460 hasConceptScore W3209858460C203092338 @default.
• W3209858460 hasConceptScore W3209858460C204787440 @default.
• W3209858460 hasConceptScore W3209858460C27081682 @default.
• W3209858460 hasConceptScore W3209858460C2775846464 @default.
• W3209858460 hasConceptScore W3209858460C2775915353 @default.
• W3209858460 hasConceptScore W3209858460C2776304953 @default.
• W3209858460 hasConceptScore W3209858460C2777428986 @default.
• W3209858460 hasConceptScore W3209858460C2778198053 @default.
• W3209858460 hasConceptScore W3209858460C2780645631 @default.
• W3209858460 hasConceptScore W3209858460C2780930700 @default.
• W3209858460 hasConceptScore W3209858460C44249647 @default.
• W3209858460 hasConceptScore W3209858460C535046627 @default.
• W3209858460 hasConceptScore W3209858460C71924100 @default.
• W3209858460 hasConceptScore W3209858460C78519656 @default.
• W3209858460 hasIssue "Supplement_1" @default.
• W3209858460 hasLocation W32098584601 @default.
• W3209858460 hasOpenAccess W3209858460 @default.
• W3209858460 hasPrimaryLocation W32098584601 @default.
• W3209858460 hasRelatedWork W1994858555 @default.
• W3209858460 hasRelatedWork W2039174841 @default.
• W3209858460 hasRelatedWork W2049397185 @default.
• W3209858460 hasRelatedWork W2060546927 @default.
• W3209858460 hasRelatedWork W2106535244 @default.
• W3209858460 hasRelatedWork W2110929951 @default.
• W3209858460 hasRelatedWork W2125804349 @default.
• W3209858460 hasRelatedWork W2355498105 @default.
• W3209858460 hasRelatedWork W3008529487 @default.
• W3209858460 hasRelatedWork W3209858460 @default.
• W3209858460 hasVolume "42" @default.
• W3209858460 isParatext "false" @default.
• W3209858460 isRetracted "false" @default.
• W3209858460 magId "3209858460" @default.
• W3209858460 workType "article" @default.